Patent · US Active

Marker genes for prostate cancer classification

US12060617B2 · kind B2 · utility

0Cited by

1References

7Claims

0Family size

Assignee

PROSTATYPE GENOMICS AB · SE

Inventors

Chunde Li · Malung, SE
Zhuochun Peng · Solna, SE
Lambert Skoog · Stockholm, SE

Key dates

Filing date	Jun 18, 2020
Grant date	Aug 13, 2024
Priority date	—
Expiry date	Mar 6, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to a method for classifying a prostate cancer in a subject, the method comprising the steps of a) determining a gene expression level or gene expression pattern of the genes F3 and IGFBP3 in a sample from the subject and b) classifying the tumor by comparing the gene expression level determined in a) with a reference gene expression of the same genes in reference patients known to have a high risk tumor respectively. In addition the invention relates to a method for determining prognosis of a subject diagnosed with prostate cancer, a method for making a treatment decision for a subject diagnosed with prostate cancer and a solid support or a kit for classifying a tumor in a subject diagnosed with prostate cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.